Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
CNY 20.8
(-0.48%)
CNY 20.8
(-0.48%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 414.37 Million CNY | 30.97% |
| 2022 | 313.2 Million CNY | 31.68% |
| 2021 | 247.42 Million CNY | 6.05% |
| 2020 | 223.9 Million CNY | 16.17% |
| 2019 | 234.75 Million CNY | 6.89% |
| 2018 | 161.3 Million CNY | 105.35% |
| 2017 | 88.16 Million CNY | 2.99% |
| 2016 | 101.25 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 113.37 Million CNY | -18.96% |
| 2024 Q1 | 99.38 Million CNY | 43.18% |
| 2024 Q2 | 130.51 Million CNY | 14.75% |
| 2023 Q4 | 75.83 Million CNY | -49.77% |
| 2023 FY | - CNY | 30.97% |
| 2023 Q3 | 150.97 Million CNY | 156.75% |
| 2023 Q2 | 58.8 Million CNY | -2.47% |
| 2023 Q1 | 60.29 Million CNY | -2.16% |
| 2022 Q3 | 55.9 Million CNY | -33.75% |
| 2022 FY | - CNY | 31.68% |
| 2022 Q2 | 84.38 Million CNY | 58.18% |
| 2022 Q1 | 53.34 Million CNY | 37.99% |
| 2022 Q4 | 61.62 Million CNY | 10.23% |
| 2021 Q2 | 53.72 Million CNY | 21.92% |
| 2021 Q1 | 44.06 Million CNY | 13.74% |
| 2021 Q4 | 38.66 Million CNY | -29.96% |
| 2021 Q3 | 55.19 Million CNY | 2.74% |
| 2021 FY | - CNY | 6.05% |
| 2020 Q1 | 58.19 Million CNY | 30.19% |
| 2020 FY | - CNY | 16.17% |
| 2020 Q4 | 38.74 Million CNY | -8.06% |
| 2020 Q3 | 42.13 Million CNY | -31.23% |
| 2020 Q2 | 61.27 Million CNY | 5.31% |
| 2019 Q4 | 44.69 Million CNY | 8.77% |
| 2019 Q3 | 41.09 Million CNY | 0.0% |
| 2019 FY | - CNY | 6.89% |
| 2018 FY | - CNY | 105.35% |
| 2017 FY | - CNY | 2.99% |
| 2016 FY | - CNY | 0.0% |